ESMO 2022 Conference Coverage
Lecture Summary - ESMO 2022 on the Global Phase 3 Multiregional Clinical Trial FRESCO-2: Evaluating the Efficacy & Safety of Fruquintinib in Refractory mCRC
By
ESMO 2022 Conference Coverage
FEATURING
Arvind Dasari
By
ESMO 2022 Conference Coverage
FEATURING
Arvind Dasari
Login to view comments.
Click here to Login
GI